19 January 2021
EMA/689345/2020
EMEA/H/C/000329

Public statement

ViraferonPeg

On 11 January 2021, the European Commission withdrew the marketing authorisation for ViraferonPeg (peginterferon alfa-2b) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Merck Sharp & Dohme B.V, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

ViraferonPeg was granted marketing authorisation in the EU on 29 May 2000 for the treatment of hepatitis C. The marketing authorisation was initially valid for a 5-year period. It was subsequently renewed for an additional 5-year period in 2005. It was then granted unlimited validity in 2010.

The European Public Assessment Report (EPAR) for ViraferonPeg will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union

© European Medicines Agency, 2020. Reproduction is authorised provided the source is acknowledged.